Treatment Overview: Pages 3-6 SenioRx Care Perspective · 2018-04-01 · UCONN ASCP is excited for the 2016-2017 school year. ... on October 21st, we will be hosting a fun, educational

Inside: Letter from the CT-ASCP President Page 2 Treatment Overview: Pages 3-6 Management of Gout in the Elderly Save the Date! Schwarting Senior Symposium 2017 Page 7 Thank you to our SSS16 Sponsors Page 8 FDA Safety Communications and Updates Page 9 ASCP Annual Meeting, Dallas, TX Page 10 Join us! Careers in Pharmacy Panel Discussion Page 11 Notes ‘n Votes— September 2016 Page 12

UConn Student Chapter Update Casandra Holveck, UConn Student Chapter President, Pharm.D. Candidate 2018

1 | Fall 2016 CT-ASCP Chapter Newsletter

UCONN ASCP is excited for the 2016-2017 school year. We have some new events we are looking forward to, as well as some

older successful events that we will be holding again. This semester, our chapter will be meeting biweekly on Tuesdays at 5pm in

the School of Pharmacy. We have mostly fresh faces on our executive board with only one seasoned member remaining. It is

comprised of President – Casandra Holveck (P3), Vice President – Kelsey Fontneau (P3), Secretary – Chelsea McDonnell (P3),

Treasurer – Bethany Carrington (P2), PSG Representative – Alexa Angerami (P2), and Historian – Stephanie Brady (P3). We are

confident this will be a fun and successful semester for our chapter.

September The first week of the semester, we participated in the “Get to Know Your Organization Ice Cream Social” for the UCONN School

of Pharmacy and met potential new professional and pre-pharmacy members. We recruited a few new pre-pharmacy students, P1s,

and P2s. We will continue to market ourselves throughout the School of Pharmacy as the semester continues to try to gain more

members.

October Our chapter is participating in a few exciting events in October. We will be walking in the Walk to End Alzheimer’s again on

October 16th at Rentschler Field, in collaboration with the UCONN Chapter of CPNP. We will be working together to raise

awareness and raise money for the cause in the Pharmacy Building Atrium the week before the walk. If anyone is interested in

helping support the Alzheimer’s Association, we highly encourage you to visit their website at www.act.alz.org to find a walk

happening near you or to make a donation. Also, on October 21st, we will be hosting a fun, educational jeopardy presentation on

drug-drug interactions at Glastonbury Senior Center. This is a new event we have organized and are looking forward to!

November We are counting down the days until the Annual meeting in Dallas, Texas! We are sending four students to this meeting and we

cannot wait for all of the CE programs and networking opportunities! We are also excited to host the CT ASCP Board of Directors

meeting at UCONN on Monday, November 7th. It will be a great way to wrap up a weekend full of learning new things about ASCP

and making connections with pharmacists from all over the country. Before the board meeting, we will also be holding a Consultant

Pharmacist panel, open to the entire school of pharmacy. The event was a hit last year, so we are looking forward to another

success.

December and Beyond

Once again our chapter will be holding a “What Not To Wear” event for all Pharmacy and Pre-Pharmacy students in order to help

them avoid making common fashion faux pas when interviewing. Student models will take to the stage in order to demonstrate

what is both appropriate and inappropriate in a professional setting. As always, if there are any opportunities to shadow at various

sites, participate in brown bag events, or volunteer for events that would allow our student chapter to further our continuing

education in consultant pharmacy, including being part of our guest lecture series, we would greatly appreciate it. Please contact

our chapter President, Casandra Holveck, at [email protected] if interested.

CT-ASCP's

SenioRx Care Perspective

Fall 2016 Volume XIII No. 2

http://www.act.alz.org


Letter from the CT-ASCP President Brian Pelletier, PharmD, CGP, FASCP

Hello CT-ASCP Members!

I wanted to send out an update on some of the goals the Board of Directors set earlier this year. Below is a

summary of what I sent in June and comments regarding our progress on these specific action items.

Membership

1. Host a networking event for all members

The BoD is planning a social networking event for Spring 2017 and more information will be sent out as we work

out the details.

2. Offer discount to Schwarting Senior Symposium (SSS)

The SSS cmte will be meeting later this year to finalize pricing for SSS 2017 (Save the Date: Thursday, April 6th,

2017)

3. Provide ‘tuition’ assistance to attend ASCP Spring Business Meeting

The BoD voted to offer registration/tuition assistance for one CT-ASCP Member to attend the ASCP Forum, which

will be held in May 2017. More information on the application process will be available in January.

Education

1. Create a needs assessment for education that will be sent to members

The evaluations received from SSS 2016 will be used to select topics for SSS 2017

2. We have hovered around 30% attendance of members at Senior Symposium the last few years – work on

increasing this number

Time will tell!

Student Involvement

1. Offer scholarships to local Universities for students (and develop corresponding criteria)

The BoD voted to offer registration/tuition assistance for two students ($500 each) to attend the ASCP Annual

Meeting. In addition to tuition assistance for the Annual meeting, the BoD is working with UCONN and USJ to

review their process for scholarships and discussing what opportunities to offer a scholarship/award for students at

these schools.

2. Discuss opportunity with student chapter(s) to help manage website, Facebook, Instagram, etc.

The student chapter from UCONN will keep the website updated and will create a presence on social media. Two

students were trained on steps to access the website and update content.

Last but not least, the Board of Directors made a small change to the By-laws, which can be viewed here.

Brian Pelletier

President, CT-ASCP

[email protected]

https://online.ascp.com/ascpssa/ecmssamsganalytics.click_through?p_mail_id=E183204A12111598B1C158781


Treatment Overview: Management of Gout in the Elderly Macayla Landi, Pharm.D., PGY-2 Geriatric Pharmacy Resident, VA Connecticut Healthcare System

Gout is a type of inflammatory arthritis caused by monosodium urate crystal deposits in synovial fluid. Development of gout

symptoms is commonly associated with hyperuricemia. Hyperuricemia is a result of urate overproduction or potential under-excretion of urate

by the kidneys.1 Gout is a condition primarily managed in the outpatient setting but also impacts those in the acute care setting with 2.3% of

38.6 million hospitalizations in 2010 contributed to gout or other crystal arthropathies.2 The Centers for Disease Control and Prevention

(CDC) report that the rate of gout among US adults from 2007-2008 was 3.9% using nationally representative data (NHANES). In addition,

prevalence of gout is higher in males compared with females and incidence increases with age.1,3 Patient-specific factors and triggers

associated with gout include insulin resistance, obesity, hypertension, renal insufficiency, congestive heart failure (CHF), alcohol intake, and

surgery.1

Gout is the most common inflammatory arthritis affecting the elderly population, with a particularly high prevalence in patients over

age 75.3 Management of gout in these patients becomes increasingly difficult and complicated in the presence of comorbidities, specifically

chronic kidney disease, as many medications used to treat gout require renal dose adjustment, as well as the potential adverse effects and drug

-drug interactions that exist. Cardiac and gastrointestinal co-morbid conditions are also important to consider in these patients due to the side

effect profiles of anti-gout agents.

Treatment of gout typically requires a “two-pronged” approach: 1) to treat an acute attack to quickly improve pain and disability and

2) for some patients, to provide chronic urate-lowering therapy (ULT) to prevent future gout flares. There are multiple therapeutic options

available for both the acute and chronic treatment of gout, however, it should be noted that some of these therapeutic options are listed as

medications to be used with caution in patients over age 65 in the American Geriatrics Society 2015 Beer’s Criteria. This includes

nonsteroidal anti-inflammatory drugs (NSAIDs) and colchicine.

Therapeutic options for management of acute gout attacks include colchicine, NSAIDs, and systemic corticosteroids. All three of

these agents may be used first-line in the management of acute gout flares, however, selecting an agent should be based on patient

characteristics and concerns, including cost, prior response, and co-morbid conditions (Table 1).4 Mild to moderate attacks of gout can

typically be managed with monotherapy, however, combination therapy may be considered in patients with severe, painful gout attacks who

do not respond to monotherapy. Although not currently considered first line, for these patients, intra-articular corticosteroids may also be

considered for larger joints.4 The combination of NSAIDs and oral corticosteroids should, however, be avoided due to potential

gastrointestinal (GI) toxicity. When NSAIDs or colchicine are contraindicated, oral and/or intra-articular corticosteroids may be used,

although there is limited evidence for use of intra-articular administration due to lack of randomized controlled trials (RCTs). The dose and

duration of any of these agents for an acute attack should be sufficient to improve gout symptoms. Despite most RCTs evaluating the use of

these medications in short duration, it may be appropriate to continue acute treatment for gout up to 10 days if required for resolution of

symptoms.4 Pharmacologic therapy should be supplemented with topical ice for acute flares.

Urate-lowering therapy for hyperuricemia and prevention of gout should be considered in patients who have had 2 or more gout

attacks per year, those with tophi, CKD stages 2 through 5, or a history of uric acid kidney stones.5 ULT should be initiated 2 to 4 weeks

following resolution of the acute attack for prevention of future flares. If initiated, ULT should be started in the elderly at low doses with dose

titration if needed over weeks to months, with close monitoring of renal function, adverse effects, and uric acid levels. Doses should be

titrated and adjusted based on response and tolerability to achieve and maintain serum uric acid (UA) levels below 6mg/dL, which has been

associated with reduced risk of recurrent flares. Some data suggests serum uric acid levels below 5mg/dL may provide further control in

preventing acute gout attacks. It is crucial that with or just prior to initiation of ULT that prophylaxis is also initiated, as ULT, which reduces

the risk of gout attacks long-term, may cause an acute attack as a result of mobilization of urate body stores. Duration of anti-inflammatory

prophylaxis when starting ULT should be continued for approximately 6 months.3

There are currently three types of medications used for ULT, including xanthine oxidase inhibitors (XOI), uricosuric agents, and

uricase agents, all of which have important considerations in the elderly population (Table 2). In the XOI class, allopurinol is the most

commonly prescribed agent. Allopurinol is a low-cost XOI with a tolerable side effect profile in most patients, however, 2% of patients will

develop a rash with this medication. In those with only mild skin rashes, allopurinol desensitization can be attempted. Many patients receive

100-300mg daily of allopurinol which is often insufficient to achieve target uric acid levels, however, doses up to 800mg may be used in

patients with normal renal function. The package insert states allopurinol dose should not exceed 200mg per day in patients with a CrCl

≤20mL/min due to concerns for increased risk of hypersensitivity. Despite this, allopurinol doses can be increased to greater than 300mg per

day even in patients with renal impairment, as long as patients are educated on risk of cutaneous reactions and are monitored closely for

tolerability, elevated LFTs, and eosinophilia.5 It should be noted that doses over 300mg daily of allopurinol should be given in divided doses.

For patients who do not tolerate or have inadequate response to allopurinol, febuxostat is typically used as a second-line XOI due to its higher

cost. If serum uric acid levels are not achieved with maximal doses of a XOI, a uricosuric agent may then be added or used as an alternative

first-line therapy.5



Probenacid and the newest FDA-approved agent for gout management, lesinurad, are the current uricosuric agents available in the

US. Probenacid is recommended as the first-line uricosuric agent, while lesiurad is not yet included in the most recent American College of

Rheumatology guidelines. Probenacid should not be used in patients with a CrCl ≤30mL/min, elevated UA indicating UA overproduction, or

with a history of kidney stones. Fenofibrate and losartan are off-label uricosuric agents which can also be added to a XOI if additional uric

acid lowering is needed.5

For elderly patients who present with hyperuricemia or confirmed gout, management should be tailored to the severity of disease,

coexisting conditions, ability to tolerate available agents, and potential drug-drug interactions. It is also essential to review medications to

ensure the patient is not taking any medications which may contribute to uric acid elevations and treatment failure; urate-neutral or

urate-lowering medications should be prescribed when possible in order to achieve treatment success (Table 3).

Table 1. Summary of therapeutic options for acute gout attacks and considerations in the elderly

Drugs Aging. 2011;28(8):591-603.

N Engl J Med. 2011; 264:443-52.

Medication Dosing options Key points and considerations in the elderly

NSAIDs

Naproxen 500mg BID x 5 days or 375-500mg BID x 4-7 days or until attack resolves

No specific NSAID is recommended over another but the most

frequently studied for gout are indomethacin and naproxen Avoid in elderly or patients with renal impairment, CHF,

bleeding disorders Associated with increased risk of GI events and bleeding May administer with a proton-pump inhibitor

Indomethacin 50mg TID x 2 days then taper to 25mg TID x 3 days or 50mg TID x 3 days then taper to 25mg TID x 4-7 days or

until attack resolves

Colchicine

1.2mg at first sign of gout flare, followed by 0.6mg 1

hours later; May consider additional acute management if needed 12-24 hours later (ie. colchicine 0.6mg QD or

BID, NSAID, or corticosteroid)

Should be started within 36 hours of symptom onset Use a lower dose in elderly patients or those with renal

impairment Adjust dose if used with Pgp or CYP3A4 inhibitors Avoid for treatment of gout flare in patients already receiving

colchicine for prophylaxis Monitor for GI symptoms, myotoxicity, and blood dyscrasias

Oral corticosteroids Prednisolone, 0.5mg/kg per day x 5-10 days then stop or

2-5 days at full dose then taper for 7-10 days then stop or

Methylprednisolone dose pack

Oral corticosteroids should be used for 5-10 days then

discontinued or tapered Intra-articular administration may be considered if unable to

tolerate oral medications, if larger joints are involved, or if

refractory to other therapies Use caution in patients with CHF or diabetes May be used in patients with moderate-severe renal impairment



Table 2. Summary of urate-lowering therapeutic (ULT) options and considerations in the elderly

Drugs Aging. 2011;28(8):591-603.

N Engl J Med. 2011; 264:443-52.

Medication Dosing options Key points and considerations in the

elderly Approximate retail

cash price

Xanthine oxidase

inhibitors

Allopurinol

Starting dose: 50mg (in elderly) to

100mg daily; Increase dose every 2-4 weeks to achieve target uric acid;

Average daily dose is 300mg for mild gout but many patients require higher

doses

Use with caution in renal

impairment If target uric acid levels are not

achieved, may continue dose escalation beyond suggested dosing

limits with close monitoring Monitor for development of rash or

hypersensitivity Doses over 300mg/day should be

given in divided doses

$10/month

Febuxostat

Starting dose: 40mg daily, increase to

80mg daily after 2-4 weeks to

achieve target uric acid level if need-ed

Use alternatively if patient develops

hypersensitivity or has inadequate response to allopurinol

Limited data in renal impairment,

use caution if CrCl <30mL/min Higher cost versus allopurinol

$200/month

Uricosuric Agents

Probenacid

Starting dose: 250mg twice daily;

Increase by 500mg every 4 weeks if

needed to a maximum dose of 2g/day in divided doses

Avoid in patients with history of

nephrolithiasis or CrCl <30mL/min Adequate hydration required to

prevent nephrolithiasis May be ineffective in patients with

moderate renal impairment

$25/month

Lesinurad 200mg once daily

Should only be used in combination

with a XOI due to risk of AKI Should be monitored with increased

frequency if CrCl <60mL/min,

discontinue if CrCl persistently

<45mL/min, contraindicated if CrCl <30mL/min

May be ineffective in patients with

moderate renal impairment

Cost not yet deter-

mined

Peglitocase

IV infusion of 8mg every 2 weeks;

requires premedication with antihista-

mines and corticosteroids, in addition to gout flare ppx 7 days before treat-

ment

Not recommended first-line,

reserved for gout prevention in patients with severe/refractory to

other agents High rates of infusion reaction

requiring premedication High cost versus other therapies

Unavailable

Flare prophylaxis during initiation of urate-lowering therapy

Colchicine 0.6mg orally once or twice daily as tolerated

See table 1 $100/month

NSAID Naproxen 250mg twice daily See table 1 $10/month



Happy Football Season Everyone!

Table 3. Common medications that may affect serum urate (SU) concentrations

Drugs Aging. 2011;28(8):591-603.

References:

Neogi T. Gout. N Engl J Med. 2011; 364: 443-52. Centers for Disease Control and Prevention (CDC). Gout. July 2016. www.cdc.gov/arthritis/basics/gout

Stamp LK, Jordan S. The challenges of gout management in the elderly. Drugs Aging. 2011; 28(8): 591-603.

Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anitiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012; 64: 1447-61.

Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systemic nonpharmacologic and

pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64: 1431-46.

Medication Class May increase SU May decrease SU No significant effect

Anti-hypertensives ------

Losartan Some ACE inhibitors (captopril,

enalapril, ramipril) Calcium channel blockers

(amlodipine, felodipine, etc.)

Lisinopril

Diuretics Furosemide Thiazides

------ Spironolactone

Lipid-lowering therapies ------ Atorvastatin Fenofibrate

Simvastatin

NSAIDs ------ Indomethacin Diclofenac Naproxen


CT-ASCP and the UConn School of Pharmacy invite you to

SAVE THE DATE

The 4th Annual

SCHWARTING SENIOR SYMPOSIUM

Thursday, April 6, 2017

The Aqua Turf Club Plantsville, CT

TWO GREAT NAMES IN CONTINUING EDUCATION

ONE AMAZING MEETING!

Arthur E. Schwarting Pharmacy Practice Symposium


Thank you to our 2016 sponsors

SCHWARTING SENIOR SYMPOSIUM

PLATINUM LEVEL

Allergan

NovoNordisk Sunovion Pharmaceuticals, Inc.

BRONZE LEVEL

Avanir Pharmaceuticals Boehringer-Ingelheim Pharmaceuticals

CT Chapter ASCP & ASCP Eli Lilly & Company

Impax Specialty Pharma Janssen Pharmaceuticals, Inc.

Lundbeck Mallinckrodt Pharmaceuticals

McKesson Omnicare, Inc.-a CVS Health Company

PharMerica Sanofi

Smith-Nephew UConn School of Pharmacy


2016 FDA Safety Communications and Updates Sarah Kessler, Pharm.D. Candidate, University of Connecticut

Opioids and Benzodiazepines

The FDA has increased the warnings on the concomitant use of opioid pain and cough medications with

benzodiazepines, warning of serious risk of death due to central nervous system depression. The combined use of

these medications has been shown to increase the risk of slowed or difficult breathing, profound sedation, coma, and/

or death. Boxed Warnings will now be issued for both pain and cough prescription opioids as well as prescription

benzodiazepines. The Warnings and Precautions, Drug Interactions, and Patient Counseling Information sections of

the labeling for both classes will be updated to reflect the noted increase in risk.

These actions are in response to FDA conducted and reviewed studies demonstrating an increasing trend in combined

prescribing, use, and abuse of opioids and benzodiazepines. The FDA found that between 2002 and 2014 the

proportion of opioid analgesic recipients receiving overlapping benzodiazepine prescriptions increased by 41 percent.

The FDA found that the subgroups with the highest probability of receiving concomitant prescriptions were

women, patients over 65, and chronic users of opioid analgesics1. The elderly are particularly at risk for adverse

events, with altered metabolism and clearance of these medications leading to increased time of effect and serious

adverse events.

Opioid pain medications and benzodiazepines should only be used when alternatives have not been successful, and

should be limited in dose and duration while achieving desired clinical effect. Patients and caregivers should be

counseled on the signs and symptoms of respiratory depression and sedation. In addition, simultaneous use of CNS

depressants, other than benzodiazepines, such as alcohol and neuroleptics, are also associated with serious adverse

events1, especially in older adults.

SGLT-2 Inhibitors and AKI

The existing warnings for acute kidney injury with canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga,

Xigduo XR) have been strengthened to reflect recently reported adverse events. This current warning does not apply

to other SGLT-2 inhibitors such as empagliflozin (Jardiance). Within a year and a half of market approval, the FDA

received 101 confirmable cases of acute kidney injury related to these medications. Hospitalization was required in

96 out of the 101 cases, with 22 of the cases involving an admission to the intensive care unit. This has prompted the

FDA to revise the warnings in the drug labels to include information about acute kidney injury and add

recommendations to minimize risk.

Before initiating canagliflozin or dapagliflozin, factors that predispose patients to acute kidney injury should be taken

into account. These include hypovolemia, chronic renal insufficiency, congestive heart failure, preexisting kidney

disease, and use of diuretics, nonsteroidal anti-inflammatory (NSAIDs), angiotensin-converting enzyme (ACE)

inhibitors, angiotensin receptor blockers (ARBs). In addition, these medications require renal dose adjustments.

Many elderly patients with polypharmacy or specific medical conditions may be poor candidates for these

medications.

References

FDA. “FDA Drug Safety Communications: FDA warns about serious risks and death when combining opioid

pain or cough medications with benzodiazepines; requires its strongest warning”. Drug Safety

Communications: Safety Announcement 8 Sept 2016.

FDA. “FDA Drug Safety Communications: FDA strengthens kidney warnings for diabetes medicines

canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)”. Drug Safety Communications:

Safety Announcement 14 Jun 2016.


Join us for the ASCP Annual Meeting

Hilton Anatole, Dallas TX

November 4-6, 2016

Register at:

www.annual.ascp.com

Curious about careers in pharmacy?

What will I do after I graduate?

What are my career options?

What is a consultant pharmacist?

Come to a CT-ASCP pharmacist panel discussion and

have your questions answered.

University of Connecticut School of Pharmacy

November 7, 2016

University of Saint Joseph School of Pharmacy

February 13, 2017

(Snow date - February 15, 2017)



SPONSOR RECOGNITION

Sponsorship: Sunovion Pharmaceuticals Inc. – Meaghan O’Connell & Chad Worz

REVIEW OF PAST MINUTES

The 8/08/16 meeting minutes were reviewed and approved (AS/KR).

CHAPTER NEWS

Secretary/Treasurer Announcement: M. Striglio has been board appointed as secretary/

treasurer with a start date of October 1st, 2016.

2016 ASCP Annual Meeting: November 4-6th in Dallas, TX. The board previously voted to

provide a NTE stipend of $1,500 for a board member to attend the national meeting and

represent the CT ASCP Chapter. D. Ciccone is planning on attending the meeting and is interested in representing the chapter. Additionally, CT ASCP members S. Jeffery,

M. Landi, and C. Liu plan on attending. During the Annual Meeting there will be time

set aside for CT ASCP members to meet. B. Pelletier will coordinate a formal/informal gathering.

SoP Meeting Dates: The CT ASCP November meeting will be held at UConn on November 7th, 2016, in addition to a pharmacy panel discussion. B. Pelletier is coordinating with

student chapter president, C. Holveck, regarding this event. Students will have recently

returned from the Annual Meeting and will have the opportunity to share their experiences. CT ASCP is in the process of determining who will be on the pharmacist

panel. The chapter is planning to have a board meeting and pharmacist panel discussion

at USJ on February 13th, 2017, with a snow date of February 15th, 2017. A. Leschak is continuing to work on recruiting students/ gauging interest and identifying who may be

the student point person for a future USJ ASCP student chapter.

Membership Outreach: A. Torda, K. Daley, and D. Ciccone are in the process of working

on an upcoming social event for students and ASCP members, which will likely occur in the springtime. Further details will be provided once available.

Student Scholarships: BoD previously voted to provide two $500 awards ($1000 total) to cover the expenses for the Fall 2016 Annual Meeting and annually thereafter. The due

date for scholarship applications will be extended to allow time for students to fill out

application. The students will complete an application with the following questions: 1) What do you hope to gain from attending the meeting? 2) What is your involvement

with improving medication use in older adults (i.e. association work/community

involvement)? The selected students will attend the November 7th BoD meeting to give a 15-minute summary of the meeting and write an article for the CT ASCP newsletter.

BoD agreed to set a tentative application due date of September 26th and applications

can be reviewed and voted upon via e-mail. Application information will be sent to students once finalized. B. Pelletier gave update from R. Eyler regarding UCONN

scholarships. The money would be contributed to the Dean’ Scholarship fund via

check and CT ASCP would need to provide a short description of who would receive the award, which would be given during the Spring term. The selected student would

be invited to the UCONN award dinner, which occurs annually in October. B. Pelletier

will discuss with C. Holveck to gain a better understanding of support from other University funding organizations (how many students are reimbursed, how much

money is provided etc.). USJ has a scholarship deadline of September 1st for award

submission, however it is possible that this date may be extended due to the fact that the chapter is still being formed. In order to create a scholarship award the following

will be needed: title, specific criteria for selection, description of award, and a review

panel.

Budget Review: B. Pelletier explained the proposed FY17 (10/2016 – 9/2017) budget and

informed chapter that adjustments can be made to the budget if needed. Budget was reviewed and discussed, then voted upon and unanimously approved (AT/KR). B.

Pelletier will send a copy of budget to Jen Sharkey at national.

Schwarting Senior Symposium: Thursday, April 6th at Aqua Turf Club in Plantsville,

CT. Save The Date postcards have been designed and are ready to be sent out. D. Ciccone will work on updating mailing list and determining who to send postcards to

(mailing list will be narrowed to solely CT addresses). J. Nault will send B. Pelletier a copy of the proposed Save The Date postcard and expected expenses (printing and

mailing costs). BoD discussed the possible need to adapt postcard to target APRN

potential attendees. Tom Frank and Dennis Chaprone are confirmed to speak at SSS. B. Pelletier has reached out to national for potential speakers for a law topic. K.

Rubinfeld will attempt to contact a potential speaker from the Department of Public

Health. D. Boggs from the VACT is interested in speaking on a psychiatric topic. B. Pelletier will confirm his availability. A psychiatric related topic in the Veteran

population has been added to the APRN requirements thus having D. Boggs speak may

potentially attract additional APRN attendees. Other potential topics ideas included: biosimilars, update on antidepressants in the elderly, and wound care. A. Leschak will

Guests: Sean Jeffery, Mike Fortin, Jill Fitzgerald, Joanne Nault, Macayla Landi, Catherine Liu, Angela Sheldon, Kelsey Fontneau, Sarah Kessler

ask APRN colleagues about topics that may interest them. B. Pelletier will ask Beth

regarding if APRN attendees could get credit for live MTM sessions as a large component of the MTM program is relevant to their practice. B. Pelletier and A.

Leschak will have conference call to discuss speakers and make finalized plans. In

addition to speakers for SSS 2017, CT ASCP will need to start brainstorming on a potential topic and presenter for April 5th, the night prior to SSS 2017.

Reviewing Leadership Concepts: B. Pelletier discussed a book entitled 5 Dysfunctions of a Team written by Patrick Lencioni. The five outlined dysfunctions include: absence

of trust, fear of conflict, lack of commitment, avoidance of accountability, and

inattention to results. The book entitled Life Worth Living by William Thomas regarding the Eden Alternative and the concept of improving meaning and importance

in long-term care facilities was discussed.

Newsletter Update: A. Torda is working on putting the newsletter together and has

reached out to C. Holveck to get a student update to include in the newsletter. The newsletter will include: a student and resident article, UCONN SoP update, Save The

Date for upcoming events, and potentially information about the student scholarship.

Meeting adjourned at 8:04 pm (KD/AT).

Next Meeting: 10/03/16 at 5:30pm Ruth’s Chris Steakhouse

(2513 Berlin Turnpike, Newington CT, 06111)

Respectfully submitted, Melissa Striglio, PharmD

CT-ASCP Board of Directors

Notes 'n Votes - September 2016 Board Meeting Melissa Striglio, PharmD, CT-ASCP Secretary / Treasurer-elect

Editorial Board Anna Torda, PharmD Kim Daley, PharmD Kevin Chamberlin, PharmD Brian Pelletier, PharmD, CGP Kristina Niehoff, PharmD, BCPS Jennifer Kloze, PharmD, BCPS

MEMBER NAME & TITLE July August September

Brian Pelletier President / Legislative Committee

X X X

Mike Gemma Immediate Past President

Karen Rubinfeld President-elect

X X

Kristina Niehoff Secretary / Treasurer, Comm. Committee

X X

Melissa Striglio Secretary / Treasurer-elect

X

Anna Torda, Board 2016-2019 / Comm. Committee

X

Dolores Ciccone Board 2016-2018

X X X

Andrea Leschak Board 2015-2018 / SSS Committee

X X X

Anna Sampieri Board 2015-2018

X X X

Kim Daley Board 2015-2017 / Comm. Committee

X X

Rachel Eyler Board 2014-2017

X

Documents

Treatment Overview: Pages 3-6 SenioRx Care Perspective · 2018-04-01 · UCONN ASCP is excited for the 2016-2017 school year. ... on October 21st, we will be hosting a fun, educational